Abstract 7145
Background
NRG1 fusions are oncogenic drivers across various cancers. NRG1 fusion proteins bind to HER3, leading to HER2/HER3 heterodimerization, increased downstream signaling, and tumor growth. Clinical responses to anti-HER3 antibodies or HER2 tyrosine kinase inhibitors have been reported. In contrast to these agents, MCLA-128 is a HER2/HER3 bispecific antibody that blocks both NRG1 binding and HER2/3 dimerization. MCLA-128 has demonstrated potent in vitro and in vivo activity in NRG1-fusion positive models. These data support the evaluation of MCLA-128 in patients with NRG1 fusion-positive tumors using a basket approach.
Trial design
This is a global, open-label, multicenter phase 2 basket trial of MCLA-128 in patients with solid tumors harboring NRG1 gene fusions. Main eligibility criteria are locally advanced unresectable or metastatic cancers harboring an NRG1 fusion, and failure under prior standard therapy appropriate for the tumor type and disease stage. Genomic screening of tumor tissue is done at a local laboratory (with post-hoc central confirmation) or central laboratory (RNA sequencing). Three NRG1 fusion-positive tumor cohorts are being evaluated: pancreatic cancer, NSCLC, and other solid tumors. The sample size for the first two cohorts is up to 25 patients; the basket group may enroll up to 40 patients. The primary endpoint for all cohorts is investigator-assessed objective response rate (RECIST v1.1). The key secondary endpoint is duration of response. Other secondary endpoints include progression-free and overall survival. Eligible patients receive a bi-weekly dosing regimen of 750 mg of MCLA-128 (2-hour infusion), every 2 weeks, in 4-week cycles. The study is actively accruing patients in North America, Europe, and Asia.
Clinical trial identification
NCT02912949.
Editorial acknowledgement
Sarah Mackenzie (PhD) from Oncology Therapeutics Development.
Legal entity responsible for the study
Merus N.V.
Funding
Merus N.V.
Disclosure
A. Drilon: Honoraria (self), Advisory / Consultancy: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint, Helsinn, Beigene, BergenBio, Hengrui, Exelixis, Tyra, Verastem, MORE Health; Research grant / Funding (institution): GlaxoSmithKline, Teva, Taiho, PharmaMar; Research grant / Funding (self): Foundation Medicine; Non-remunerated activity/ies: Wolters Kluwer, Merck, Puma . T. Macarulla Mercade: Honoraria (self): Shire Pharmaceuticals, Roche, Tesaro, Batxer, Sanofi, Celgene, QED Therapeutics, Genzyme Europe, Baxalta, Bayer, Incyte, Servier, Lilly, Ipsen; Travel / Accommodation / Expenses: Merck, H3 Biomedicine, Bayer, Sanofi, Servier. E.M. O’Reilly: Research grant / Funding (institution): Genentech, BMS, Halozyme, Celgene, MabVax Therapeutics, ActaBiologica, AstraZeneca, Silenseed, Pfizer, Polaris; Advisory / Consultancy: CytomX Therapeutics, BioLineRx, Targovax, Ipsen, Celgene, Bayer, Polaris, Sobi, Merck. J.A. Rodon: Travel / Accommodation / Expenses: European Journal of Cancer, Vall d’Hebron Institut of Oncology, Chinese University of Hong Kong, SOLTI, Elsevier, GlaxoSmithKline, ESMO, US Department of Defense, Louissiana State University, Hunstman Cancer Institute, Cancer Core Europe, Karolinska Cancer; Advisory / Consultancy: Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals Inc, Pfizer, Roche Pharmaceuticals, Ellipses Pharma; Research grant / Funding (institution): Bayer and Novartis; Non-remunerated activity/ies: Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GlaxoSmithKline, Ipsen. B.M. Wolpin: Research grant / Funding (institution): Celgene Inc., Eli Lilly and Company; Advisory / Consultancy: BioLineRx Ltd., Celgene Inc., G1 Therapeutics Inc., and GRAIL Inc. S.I. Ou: Honoraria (self): Pfizer, Roche/Genentech/Ignyta/Foundation Medicine, Astra Zeneca, Merck, Takeda/ARIAD; Advisory / Consultancy: Turning Point (TP) Therapeutics; Shareholder / Stockholder / Stock options: Turning Point Therapeutics. J.C. Yang: Honoraria (self): Boehringer Ingelheim, Eli Lilly, Bayer, Roche/, Chugai, Astellas, Merck Serono, MSD, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceuticals, Daiichi Sankyo, Hansoh Pharmaceuticals, Takeda Pharmaceuticals, Blueprint Medicines. A. Varga: Research grant / Funding (institution): Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Research grant / Funding (institution), drug supply: Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. A.J. de Langen: Research grant / Funding (institution): Boehringer, AstraZeneca, Merck / MSD, BMS; Non-remunerated activity/ies, non-financial support: Roche; Honoraria (self): Merck / MSD, BMS. V. Boni: Honoraria (self), Research grant / Funding (institution): Loxo Therapeutics; Advisory / Consultancy: OncoArt; Advisory / Consultancy: Guidepoint; Speaker Bureau / Expert testimony: SOLTI; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): PUMA; Research grant / Funding (institution): Kura; Research grant / Funding (institution): Cytomex; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Seattle Genetics; Travel / Accommodation / Expenses: START. M. Duruisseaux: Advisory / Consultancy, Research grant / Funding (institution), Personal fees for expertise / Consulting : Pfizer; Advisory / Consultancy, Research grant / Funding (institution), Personal fees for expertise / Consulting : Novartis; Research grant / Funding (institution): Nanostring; Advisory / Consultancy, Personal fees for expertise / Consulting : Roche; Advisory / Consultancy, Personal fees for expertise / Consulting : Takeda; Advisory / Consultancy, Personal fees for expertise / Consulting: AbbVie; Advisory / Consultancy, Personal fees for expertise / Consulting: MSD; Advisory / Consultancy, Personal fees for expertise / Consulting : BI; Advisory / Consultancy, Personal fees for expertise / Consulting : BMS; Advisory / Consultancy, Personal fees for expertise / Consulting : AZ. S.V. Liu: Advisory / Consultancy: Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Heron, Ignyta, Inivata, Janssen, Lilly, Merck, Pfizer, Regeneron, Taiho (DSMB), Takeda/Ariad, Tempus; Research grant / Funding (institution): Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Clovis, Corvus, Debiopharm, Esanex, Genentech/Roche, Ignyta, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Pfizer, Rain Therapeutics. E. Wasserman: Full / Part-time employment: Merus NV; Shareholder / Stockholder / Stock options: Merus NV. D.M. Hyman: Shareholder / Stockholder / Stock options: Fount; Consulting or Advisory Role: Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Genentech, Fount; Research grant / Funding (institution): AstraZeneca, Puma Biotechnology, Loxo, Bayer; Travel, Accommodations, Expenses: Genentech, Chugai Pharma. J. Tabernero: Advisory / Consultancy: Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Part. All other authors have declared no conflicts of interest.
Resources from the same session
5203 - Novel fusion genes identified from matched primary and recurred breast cancers by RNA-sequencing
Presenter: Soojeong Choi
Session: Poster Display session 2
Resources:
Abstract
5873 - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
Presenter: Donna Fitzgerald
Session: Poster Display session 2
Resources:
Abstract
3588 - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: a translational approach.
Presenter: Anna Adam-Artigues
Session: Poster Display session 2
Resources:
Abstract
5640 - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
Presenter: Marija Balic
Session: Poster Display session 2
Resources:
Abstract
2616 - Clinical application of mutational analysis in breast cancer patients: the relevance of PIK3CA analysis for precision medicine.
Presenter: Juan Miguel Cejalvo
Session: Poster Display session 2
Resources:
Abstract
3870 - A retrospective gene expression analysis of surgically-removed Breast Cancer Brain Metastasis (BCBM)
Presenter: Meritxell Mallafré-Larrosa
Session: Poster Display session 2
Resources:
Abstract
1240 - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: meta-analysis of Phase II and III randomized clinical trials
Presenter: Claudia Omarini
Session: Poster Display session 2
Resources:
Abstract
5535 - Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): management and time course of key adverse events of special interest (AESIs) in SOLAR-1
Presenter: Hope Rugo
Session: Poster Display session 2
Resources:
Abstract
3093 - Changes in Hormone-Receptor status in Luminal breast cancers between primary tumor and metastases: results of the observational cohort GIM-13 AMBRA Study
Presenter: Marina Cazzaniga
Session: Poster Display session 2
Resources:
Abstract
1378 - MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
Presenter: Miguel Martín
Session: Poster Display session 2
Resources:
Abstract